We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+8.84%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$1.5B
AUM Growth
+$2.79M
Cap. Flow
+$38.8M
Cap. Flow %
2.58%
Top 10 Hldgs %
78.81%
Holding
41
New
6
Increased
3
Reduced
5
Closed
2

Top Buys

Rank Stock Value
1
NGNE icon
Neurogene
NGNE
+$28.7M
2
SEPN
Septerna Inc
SEPN
+$13.1M
3
BEAM icon
Beam Therapeutics
BEAM
+$12.1M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$11.7M
5
MRNA icon
Moderna
MRNA
+$8.36M

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$20.9M
2
VCYT icon
Veracyte
VCYT
+$14.8M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$7.89M
4
GRAL
GRAIL Inc
GRAL
+$4.82M
5
RNAM
Avidity Biosciences
RNAM
+$1.66M

Sector Composition

Rank Sector Weight
1 Healthcare 99.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WGS icon
1
GeneDx Holdings
WGS
$1.98B
$270M 17.94%
3,507,164
– –
BLFS icon
2
BioLife Solutions
BLFS
$1.56B
$226M 15.04%
8,707,165
– –
RVMD icon
3
Revolution Medicines
RVMD
$38.8B
$162M 10.77%
3,699,283
-415,000
-10% -$20.9M
SRPT icon
4
Sarepta Therapeutics
SRPT
$1.63B
$131M 8.69%
1,073,500
– –
LAB icon
5
Standard BioTools
LAB
$343M
$125M 8.3%
71,254,677
– –
ILMN icon
6
Illumina
ILMN
$30.2B
$100M 6.67%
750,000
– –
RNAM
7
DELISTED
Avidity Biosciences
RNAM
$59.5M 3.96%
2,045,000
-39,841
-2% -$1.66M
CDXS icon
8
Codexis
CDXS
$157M
$38.6M 2.57%
8,100,000
– –
RLAY icon
9
Relay Therapeutics
RLAY
$4.04B
$36.9M 2.45%
8,948,574
-302,534
-3% -$1.65M
EXAS
10
DELISTED
Exact Sciences
EXAS
$36.5M 2.43%
650,000
– –
ALNY icon
11
Alnylam Pharmaceuticals
ALNY
$29.1B
$32.9M 2.19%
140,000
-30,000
-18% -$7.89M
BEAM icon
12
Beam Therapeutics
BEAM
$2.66B
$31M 2.06%
1,250,000
+475,000
+61% +$12.1M
NGNE icon
13
Neurogene
NGNE
$657M
$29.6M 1.97%
1,295,361
+770,745
+147% +$28.7M
BPMC
14
DELISTED
Blueprint Medicines
BPMC
$28.5M 1.89%
326,378
– –
NTLA icon
15
Intellia Therapeutics
NTLA
$1.5B
$23.3M 1.55%
2,000,000
– –
VERV
16
DELISTED
Verve Therapeutics
VERV
$22.5M 1.5%
3,995,571
– –
DNLI icon
17
Denali Therapeutics
DNLI
$3.67B
$20.2M 1.34%
990,000
– –
GPCR icon
18
Structure Therapeutics
GPCR
$3.39B
$19M 1.26%
700,000
– –
SEPN
19
Septerna Inc
SEPN
$1.57B
$12.7M 0.84%
+553,268
New +$13.1M
VCYT icon
20
Veracyte
VCYT
$3.6B
$10.9M 0.73%
276,308
-390,000
-59% -$14.8M
GH icon
21
Guardant Health
GH
$21.6B
$10.7M 0.71%
350,000
– –
TNYA icon
22
Tenaya Therapeutics
TNYA
$161M
$9.63M 0.64%
6,732,971
– –
AGIO icon
23
Agios Pharmaceuticals
AGIO
$1.84B
$8.21M 0.55%
+250,000
New +$11.7M
MRNA icon
24
CALL
Moderna
MRNA
$22.1B
$7.28M 0.48%
+175,000
New +$8.36M
MRNA icon
25
Moderna
MRNA
$22.1B
$7.28M 0.48%
+175,000
New +$8.36M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.33B AUM 32.43% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return

Casdin Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Casdin Capital held 41 positions worth $1.5B, up 0.19% from $1.5B the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Casdin Capital's Q4 2024 filing shows 6 new, 3 increased, 5 reduced and 2 closed positions. Its largest new stake was Septerna Inc: 553,268 shares worth $12.7M. The largest sale was Revolution Medicines, an estimated $20.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

  • Casdin Capital's largest Q4 2024 buy was Septerna Inc: 553,268 shares worth $12.7M.
  • Casdin Capital added most to Neurogene in Q4 2024, an estimated $28.7M increase.
  • Casdin Capital's biggest Q4 2024 reduction was Revolution Medicines, cutting an estimated $20.9M.
  • Casdin Capital fully exited GRAIL Inc in Q4 2024, selling an estimated $4.82M.
  • Casdin Capital's ten largest holdings make up 79% of its $1.5B portfolio in Q4 2024.
  • Casdin Capital opened 6 new positions and closed 2 in Q4 2024.
  • Casdin Capital's portfolio value rose 0.19% quarter-over-quarter to $1.5B.

Based on Casdin Capital's 13F filing for Q4 2024, filed 14 Feb 2025.